This proposal is in response to RFA-NS-02-010 Parkinson's Disease Neuroprotective Clinical Trials: Clinical Center. Parkinson's disease is a progressive and debilitating neurodegenerative disorder affecting one-percent of the population over the age of 55 years. The primary pathological features of PD are the loss of nigrostriatal dopaminergic neurons and subsequent depletion of striatal dopamine. The cause of PD is currently unknown but both environmental and genetic factors may contribute to the etiology of the disease. Since PD is a progressive disease, pharmacological and/or non-pharmacological modalities may be developed to provide neuroprotection through either protecting/rescuing surviving neurons and slowing disease progression. The primary goal of this proposal is to identify and recruit patients and conduct clinical trials of neuroprotection in early stage PD. An alternative approach to slowing disease progression is by promoting neuroplasticity in surviving nigrostriatal neurons. One possible non-pharmacological intervention is the process of activity-dependent neuroplasticity that may be achieved through long-term exercise (such as treadmill training). The secondary goal of this proposal is to determine if long-term treadmill training attenuates disease progression in PD through activity dependent neuroplasticity.
|Wills, Anne-Marie A; Pérez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8|
|Elm, Jordan J; NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27:1513-21|